VistaGen Therapeutics (NASDAQ: VTGN), a biopharmaceutical company committed to developing and commercializing a new generation of medicines with the potential to go beyond the current standard of care for anxiety, depression and other central nervous system (“CNS”) disorders, has scheduled a Nov. 10, 2021, conference call and webcast. During the call, which is slated to begin at 5 p.m. ET, company officials will report financial results for the quarter ended Sept. 30, 2021. They will also provide an overview of recent accomplishments and developments as well as upcoming milestones. Those interested can participate in the call by dialing 1-877-407-9716 in the United States and using conference ID 13724394. International callers can dial 1-201-493-6779 and use the same conference ID. The call will also be available via a live audio webcast, which can be accessed 10 minutes prior to the event starting. A telephone playback of the call will also be available. Those interested in listening to that can call toll free 1-844-512-2921 within the United States or 1-412-317-6671 internationally, and use the replay PIN number 13724394.

To view the webcast, visit https://ibn.fm/iAoRB

To view the full press release, visit https://ibn.fm/YKfSO

About VistaGen Therapeutics Inc.

VistaGen Therapeutics is a biopharmaceutical company committed to developing and commercializing innovative medicines with the potential to go beyond the current standard of care for anxiety, depression and other CNS disorders. Each of VistaGen’s drug candidates has a differentiated profile and therapeutic potential in multiple CNS markets. For more information about the company, please visit www.VistaGen.com.

NOTE TO INVESTORS: The latest news and updates relating to VTGN are available in the company’s newsroom at https://ibn.fm/VTGN

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.

With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.

Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@InvestorWire.com

InvestorWire is part of the InvestorBrandNetwork.